Li Zizhi, Li Junyi, Cao Qingfei, Shen Tong, Wang Yingjie, He Haoyang, Tong Ming
Department of Medicine, Soochow University, Soochow, Jiangsu, China; Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
J Biol Chem. 2025 Jan;301(1):108024. doi: 10.1016/j.jbc.2024.108024. Epub 2024 Nov 26.
Bladder cancer is notorious for its high recurrence and costly treatment burden, prompting a search for novel therapeutic targets. Our study focuses on HSPB6, a small heat shock protein whose reduced expression in bladder cancer suggests a role in tumor biology. Using an integrative approach of bioinformatics, RNA sequencing, and cell-based assays, we show that HSPB6 upregulation inhibits cancer cell proliferation and metastasis while promoting apoptosis. Moreover, TCF7L1-mediated upregulation of HSPB6 leads to suppression of the PI3K/AKT/mTOR signaling pathway, a key driver of cancer progression. These results position HSPB6 as a compelling target for bladder cancer therapy, and its regulatory role in the PI3K/AKT/mTOR axis underscores its therapeutic potential. Our findings pave the way for future investigations into HSPB6-centered treatment strategies.
膀胱癌因其高复发率和高昂的治疗负担而声名狼藉，这促使人们寻找新的治疗靶点。我们的研究聚焦于HSPB6，一种小分子热休克蛋白，其在膀胱癌中的表达降低表明它在肿瘤生物学中发挥作用。通过生物信息学、RNA测序和细胞实验的综合方法，我们发现HSPB6的上调抑制癌细胞增殖和转移，同时促进细胞凋亡。此外，TCF7L1介导的HSPB6上调导致PI3K/AKT/mTOR信号通路受到抑制，而该信号通路是癌症进展的关键驱动因素。这些结果表明HSPB6是膀胱癌治疗的一个有吸引力的靶点，其在PI3K/AKT/mTOR轴中的调节作用突出了其治疗潜力。我们的研究结果为未来以HSPB6为中心的治疗策略研究铺平了道路。
